-
1
-
-
84865285654
-
Effect of nilotinib (NIL) on molecular response in chronic myelogenous leukemia - chronic phase (CML-CP) patients (pts) with a suboptimal molecular response to imatinib (IM)-ENABL study update
-
118(abstract 2771)
-
Ailawadhi S., Miller C.B., Jillela A.P., Koshy N., Tudor B., Akard L.P. Effect of nilotinib (NIL) on molecular response in chronic myelogenous leukemia - chronic phase (CML-CP) patients (pts) with a suboptimal molecular response to imatinib (IM)-ENABL study update. Blood 2011, 118(abstract 2771).
-
(2011)
Blood
-
-
Ailawadhi, S.1
Miller, C.B.2
Jillela, A.P.3
Koshy, N.4
Tudor, B.5
Akard, L.P.6
-
2
-
-
68549098145
-
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
-
Alvarado Y., Kantarjian H., O'Brien S., Faderl S., Borthakur G., Burger J., et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009, 115:3709-3718.
-
(2009)
Cancer
, vol.115
, pp. 3709-3718
-
-
Alvarado, Y.1
Kantarjian, H.2
O'Brien, S.3
Faderl, S.4
Borthakur, G.5
Burger, J.6
-
3
-
-
73349122639
-
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
-
Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 2009, 27:6041-6051.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 6041-6051
-
-
Baccarani, M.1
Cortes, J.2
Pane, F.3
Niederwieser, D.4
Saglio, G.5
Apperley, J.6
-
4
-
-
84881298446
-
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
-
Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.
-
(2013)
Blood
, vol.122
, pp. 872-884
-
-
Baccarani, M.1
Deininger, M.W.2
Rosti, G.3
Hochhaus, A.4
Soverini, S.5
Apperley, J.F.6
-
5
-
-
78651337547
-
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
-
Bixby D., Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011, 25:7-22.
-
(2011)
Leukemia
, vol.25
, pp. 7-22
-
-
Bixby, D.1
Talpaz, M.2
-
7
-
-
84915745986
-
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
-
Brümmendorf T.H., Cortes J.E., de Souza C.A., Guilhot F., Duvillié L., Pavlov D., et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br. J. Haematol. 2015, 168:69-81.
-
(2015)
Br. J. Haematol.
, vol.168
, pp. 69-81
-
-
Brümmendorf, T.H.1
Cortes, J.E.2
de Souza, C.A.3
Guilhot, F.4
Duvillié, L.5
Pavlov, D.6
-
8
-
-
84870752970
-
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib
-
Branford S., Kim D.W., Soverini S., Haque A., Shou Y., Woodman R.C., et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J. Clin. Oncol. 2012, 30:4323-4329.
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 4323-4329
-
-
Branford, S.1
Kim, D.W.2
Soverini, S.3
Haque, A.4
Shou, Y.5
Woodman, R.C.6
-
9
-
-
84880496470
-
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
-
Branford S., Yeung D.T., Ross D.M., Prime J.A., Field C.R., Altamura H.K., et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013, 121:3818-3824.
-
(2013)
Blood
, vol.121
, pp. 3818-3824
-
-
Branford, S.1
Yeung, D.T.2
Ross, D.M.3
Prime, J.A.4
Field, C.R.5
Altamura, H.K.6
-
10
-
-
84904887484
-
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
-
Branford S., Yeung D.T., Parker W.T., Roberts N.D., Purins L., Braley J.A., et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014, 124:511-518.
-
(2014)
Blood
, vol.124
, pp. 511-518
-
-
Branford, S.1
Yeung, D.T.2
Parker, W.T.3
Roberts, N.D.4
Purins, L.5
Braley, J.A.6
-
11
-
-
84884729410
-
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients
-
Cerrano M., Crisa E., Pregno P., Aguzzi C., Riccomagno P., Boccadoro M., et al. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients. Am. J. Hematol. 2013, 88:838-842.
-
(2013)
Am. J. Hematol.
, vol.88
, pp. 838-842
-
-
Cerrano, M.1
Crisa, E.2
Pregno, P.3
Aguzzi, C.4
Riccomagno, P.5
Boccadoro, M.6
-
12
-
-
84974563240
-
Efficacy of nilotinib vs high-dose imatinib vs sustaining standard-dose imatinib in early chronic phase CML patients who have suboptimal molecular response to frontline imatinib
-
Choi S.Y., Lee S.E., Kim S.H., Woodman R., Szczudlo T., Jootar S., et al. Efficacy of nilotinib vs high-dose imatinib vs sustaining standard-dose imatinib in early chronic phase CML patients who have suboptimal molecular response to frontline imatinib. Haematologica 2015, 100. (abstract E1102).
-
(2015)
Haematologica
, pp. 100
-
-
Choi, S.Y.1
Lee, S.E.2
Kim, S.H.3
Woodman, R.4
Szczudlo, T.5
Jootar, S.6
-
13
-
-
84908610113
-
Change in chronic low-grade nonhematologic adverse events (AEs) and quality of life (QoL) in adult patients (pts) with Philadelphia chromosome-positive (Ph +) chronic myeloid leukemia in chronic phase (CML-CP) switched from imatinib (IM) to nilotinib (NIL)
-
Cortes J.E., Lipton J.H., Miller C.B., Ailawadhi S., Akard L., Pinilla-Ibarz J., et al. Change in chronic low-grade nonhematologic adverse events (AEs) and quality of life (QoL) in adult patients (pts) with Philadelphia chromosome-positive (Ph +) chronic myeloid leukemia in chronic phase (CML-CP) switched from imatinib (IM) to nilotinib (NIL). Blood 2012, 120. (abstract 3782).
-
(2012)
Blood
, pp. 120
-
-
Cortes, J.E.1
Lipton, J.H.2
Miller, C.B.3
Ailawadhi, S.4
Akard, L.5
Pinilla-Ibarz, J.6
-
14
-
-
84900008804
-
Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis
-
Deangelo D.J., Chen L., Guerin A., Styles A., Giguere-Duval P., Wu E.Q. Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis. Clin. Lymphoma Myeloma Leuk 2014, 14:245-251.
-
(2014)
Clin. Lymphoma Myeloma Leuk
, vol.14
, pp. 245-251
-
-
Deangelo, D.J.1
Chen, L.2
Guerin, A.3
Styles, A.4
Giguere-Duval, P.5
Wu, E.Q.6
-
15
-
-
0037438640
-
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
-
Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
-
(2003)
Blood
, vol.101
, pp. 690-698
-
-
Donato, N.J.1
Wu, J.Y.2
Stapley, J.3
Gallick, G.4
Lin, H.5
Arlinghaus, R.6
-
16
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417.
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
-
17
-
-
80055086681
-
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
-
Efficace F., Baccarani M., Breccia M., Alimena G., Rosti G., Cottone F., et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011, 118:4554-4560.
-
(2011)
Blood
, vol.118
, pp. 4554-4560
-
-
Efficace, F.1
Baccarani, M.2
Breccia, M.3
Alimena, G.4
Rosti, G.5
Cottone, F.6
-
18
-
-
84894276295
-
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors
-
Efficace F., Rosti G., Cottone F., Breccia M., Castagnetti F., Iurlo A., et al. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leuk. Res. 2014, 38:294-298.
-
(2014)
Leuk. Res.
, vol.38
, pp. 294-298
-
-
Efficace, F.1
Rosti, G.2
Cottone, F.3
Breccia, M.4
Castagnetti, F.5
Iurlo, A.6
-
19
-
-
84895748178
-
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib frontline therapy
-
Etienne G., Dulucq S., Nicolini F.E., Morrisset S., Fort M.P., Schmitt A., et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib frontline therapy. Haematologica 2014, 99:458-464.
-
(2014)
Haematologica
, vol.99
, pp. 458-464
-
-
Etienne, G.1
Dulucq, S.2
Nicolini, F.E.3
Morrisset, S.4
Fort, M.P.5
Schmitt, A.6
-
20
-
-
0042305479
-
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients
-
Gambacorti-Passerini C., Zucchetti M., Russo D., Frapolli R., Verga M., Bungaro S., et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin. Cancer Res. 2003, 9:625-632.
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 625-632
-
-
Gambacorti-Passerini, C.1
Zucchetti, M.2
Russo, D.3
Frapolli, R.4
Verga, M.5
Bungaro, S.6
-
21
-
-
84902843429
-
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up
-
Gambacorti-Passerini C., Brümmendorf T.H., Kim D.W., Turkina A.G., Masszi T., Assouline S., et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am. J. Hematol. 2014, 89:732-742.
-
(2014)
Am. J. Hematol.
, vol.89
, pp. 732-742
-
-
Gambacorti-Passerini, C.1
Brümmendorf, T.H.2
Kim, D.W.3
Turkina, A.G.4
Masszi, T.5
Assouline, S.6
-
22
-
-
85027935126
-
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
-
García-Gutiérrez V., Puerta J.M., Maestro B., Casado Montero L.F., Muriel A., Molina Hurtado J.R., et al. Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?. Am. J. Hematol. 2014, 89:E206-E211.
-
(2014)
Am. J. Hematol.
, vol.89
, pp. E206-E211
-
-
García-Gutiérrez, V.1
Puerta, J.M.2
Maestro, B.3
Casado Montero, L.F.4
Muriel, A.5
Molina Hurtado, J.R.6
-
23
-
-
84873568081
-
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
-
Giles F.J., le Coutre P.D., Pinilla-Ibarz J., Larson R.A., Gattermann N., Ottmann O.G., et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013, 27:107-112.
-
(2013)
Leukemia
, vol.27
, pp. 107-112
-
-
Giles, F.J.1
le Coutre, P.D.2
Pinilla-Ibarz, J.3
Larson, R.A.4
Gattermann, N.5
Ottmann, O.G.6
-
24
-
-
84974595371
-
-
Novartis Pharmaceuticals Corporation, East Hanover, NJ
-
Gleevec (imatinib) [Package Insert] 2015, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
-
(2015)
Gleevec (imatinib) [Package Insert]
-
-
-
25
-
-
84908610333
-
Impact of low-grade averse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
-
Guérin A., Chen L., Ionescu-Ittu R., Marynchenko M., Nitulescu R., Hiscock R., et al. Impact of low-grade averse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Curr. Med. Res. Opin. 2014, 30:2317-2328.
-
(2014)
Curr. Med. Res. Opin.
, vol.30
, pp. 2317-2328
-
-
Guérin, A.1
Chen, L.2
Ionescu-Ittu, R.3
Marynchenko, M.4
Nitulescu, R.5
Hiscock, R.6
-
26
-
-
84921801141
-
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
-
Hanfstein B., Shlyakhto V., Lauseker M., Hehlmann R., Saussele S., Dietz C., et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014, 28:1988-1992.
-
(2014)
Leukemia
, vol.28
, pp. 1988-1992
-
-
Hanfstein, B.1
Shlyakhto, V.2
Lauseker, M.3
Hehlmann, R.4
Saussele, S.5
Dietz, C.6
-
27
-
-
70350132811
-
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
-
Hegedus C., Ozvegy-Laczka C., Apati A., Magocsi M., Nemet K., Orfi L., et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol. 2009, 158:1153-1164.
-
(2009)
Br. J. Pharmacol.
, vol.158
, pp. 1153-1164
-
-
Hegedus, C.1
Ozvegy-Laczka, C.2
Apati, A.3
Magocsi, M.4
Nemet, K.5
Orfi, L.6
-
28
-
-
84897574239
-
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV
-
Hehlmann R., Müller M.C., Lauseker M., Hanfstein B., Fabarius A., Schreiber A., et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J. Clin. Oncol. 2014, 32:415-423.
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. 415-423
-
-
Hehlmann, R.1
Müller, M.C.2
Lauseker, M.3
Hanfstein, B.4
Fabarius, A.5
Schreiber, A.6
-
29
-
-
84903604018
-
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily
-
Hughes T.P., Hochhaus A., Kantarjian H.M., Cervantes F., Guilhot F., Niederwieser D., et al. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily. Haematologica 2014, 99:1204-1211.
-
(2014)
Haematologica
, vol.99
, pp. 1204-1211
-
-
Hughes, T.P.1
Hochhaus, A.2
Kantarjian, H.M.3
Cervantes, F.4
Guilhot, F.5
Niederwieser, D.6
-
30
-
-
84905114999
-
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib
-
Hughes T.P., Lipton J.H., Spector N., Cervantes F., Pasquini R., Clementino N.C.D., et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood 2014, 124:729-736.
-
(2014)
Blood
, vol.124
, pp. 729-736
-
-
Hughes, T.P.1
Lipton, J.H.2
Spector, N.3
Cervantes, F.4
Pasquini, R.5
Clementino, N.C.D.6
-
31
-
-
84897007532
-
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
-
Hughes T.P., Saglio G., Kantarjian H.M., Guilhot F., Niederwieser D., Rosti G., et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014, 123:1353-1360.
-
(2014)
Blood
, vol.123
, pp. 1353-1360
-
-
Hughes, T.P.1
Saglio, G.2
Kantarjian, H.M.3
Guilhot, F.4
Niederwieser, D.5
Rosti, G.6
-
32
-
-
84974576916
-
ENESTcmr 4-year results: patients with chronic myeloid leukemia in chronic phase and resisdual disease more likely to achieve deep molecular response following switch to nilotinib
-
Hughes T.P., Cervantes F., Leber B., Spector N., Lipton J.H., Pasquini R., et al. ENESTcmr 4-year results: patients with chronic myeloid leukemia in chronic phase and resisdual disease more likely to achieve deep molecular response following switch to nilotinib. Haematologica 2015, 100. (abstract P229).
-
(2015)
Haematologica
, pp. 100
-
-
Hughes, T.P.1
Cervantes, F.2
Leber, B.3
Spector, N.4
Lipton, J.H.5
Pasquini, R.6
-
33
-
-
79953823237
-
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
-
Ibrahim A.R., Eliasson L., Apperley J.F., Milojkovic D., Bua M., Szydlo R., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011, 117:3733-3736.
-
(2011)
Blood
, vol.117
, pp. 3733-3736
-
-
Ibrahim, A.R.1
Eliasson, L.2
Apperley, J.F.3
Milojkovic, D.4
Bua, M.5
Szydlo, R.6
-
35
-
-
84960941451
-
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
-
Imagawa J., Tanaka H., Okada M., Nakamae H., Hino M., Murai K., et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015, 2:e528-e535.
-
(2015)
Lancet Haematol.
, vol.2
, pp. e528-e535
-
-
Imagawa, J.1
Tanaka, H.2
Okada, M.3
Nakamae, H.4
Hino, M.5
Murai, K.6
-
36
-
-
84893136765
-
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
-
Jabbour E., Kantarjian H.M., Saglio G., Steegmann J.L., Shah N.P., Boqué C., et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014, 123:494-500.
-
(2014)
Blood
, vol.123
, pp. 494-500
-
-
Jabbour, E.1
Kantarjian, H.M.2
Saglio, G.3
Steegmann, J.L.4
Shah, N.P.5
Boqué, C.6
-
37
-
-
84857731311
-
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
-
Kantarjian H., O'Brien S., Jabbour E., Garcia-Manero G., Quintas-Cardama A., Shan J., et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012, 119:1981-1987.
-
(2012)
Blood
, vol.119
, pp. 1981-1987
-
-
Kantarjian, H.1
O'Brien, S.2
Jabbour, E.3
Garcia-Manero, G.4
Quintas-Cardama, A.5
Shan, J.6
-
38
-
-
84900848919
-
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
-
Kim D.D., Hamad N., Lee H.G., Kamel-Reid S., Lipton J.H. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am. J. Hematol. 2014, 89:626-632.
-
(2014)
Am. J. Hematol.
, vol.89
, pp. 626-632
-
-
Kim, D.D.1
Hamad, N.2
Lee, H.G.3
Kamel-Reid, S.4
Lipton, J.H.5
-
39
-
-
84974571095
-
Dasatinib in patients with chronic phase chronic meloid leukemia with persistent, low-grade nonhematologic toxicity to imatinib: results from Dasperse (CA180-400)
-
Kim D.W., Cleeland C.S., Saussele S., Williams L.A., Mohamed H., Pinilla-Ibarz J., et al. Dasatinib in patients with chronic phase chronic meloid leukemia with persistent, low-grade nonhematologic toxicity to imatinib: results from Dasperse (CA180-400). Blood 2015, 126. (abstract 1575).
-
(2015)
Blood
, pp. 126
-
-
Kim, D.W.1
Cleeland, C.S.2
Saussele, S.3
Williams, L.A.4
Mohamed, H.5
Pinilla-Ibarz, J.6
-
40
-
-
84867395848
-
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
-
Larson R.A., Hochhaus A., Hughes T.P., Clark R.E., Etienne G., Kim D.W., et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012, 26:2197-2203.
-
(2012)
Leukemia
, vol.26
, pp. 2197-2203
-
-
Larson, R.A.1
Hochhaus, A.2
Hughes, T.P.3
Clark, R.E.4
Etienne, G.5
Kim, D.W.6
-
41
-
-
84936962878
-
Ponatinib in patients (pts) with philadelphia chromosome-positive (ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow-up of the PACE trial
-
le Coutre P.D., Kim D.W., Pinilla-Ibarz J., Paquette R., Chuah C., Nicolini F.E., et al. Ponatinib in patients (pts) with philadelphia chromosome-positive (ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: longer-term follow-up of the PACE trial. Haematologica 2014, 99. (abstract P893).
-
(2014)
Haematologica
, pp. 99
-
-
le Coutre, P.D.1
Kim, D.W.2
Pinilla-Ibarz, J.3
Paquette, R.4
Chuah, C.5
Nicolini, F.E.6
-
42
-
-
84974549428
-
Final LASOR results: switch to nilotinib in patients with chronic myeloid leukemia in chronic phase and suboptimal cytogenetic response to frontline imatinib
-
le Coutre P.D., Shah S., De Souza C.A., Ayala M., Lopez J.L., Bullorsky E., et al. Final LASOR results: switch to nilotinib in patients with chronic myeloid leukemia in chronic phase and suboptimal cytogenetic response to frontline imatinib. Haematologica 2015, 100. (abstract P232).
-
(2015)
Haematologica
, pp. 100
-
-
le Coutre, P.D.1
Shah, S.2
De Souza, C.A.3
Ayala, M.4
Lopez, J.L.5
Bullorsky, E.6
-
43
-
-
84892718446
-
Deep molecular response in chronic myeloid leukemia: the new goal of therapy
-
Mahon F.X., Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy. Clin. Cancer Res. 2014, 20:310-322.
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 310-322
-
-
Mahon, F.X.1
Etienne, G.2
-
44
-
-
57149098598
-
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression
-
Mahon F.X., Hayette S., Lagarde V., Belloc F., Turcq B., Nicolini F., et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res. 2008, 68:9809-9816.
-
(2008)
Cancer Res.
, vol.68
, pp. 9809-9816
-
-
Mahon, F.X.1
Hayette, S.2
Lagarde, V.3
Belloc, F.4
Turcq, B.5
Nicolini, F.6
-
45
-
-
78049528573
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
-
Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11:1029-1035.
-
(2010)
Lancet Oncol.
, vol.11
, pp. 1029-1035
-
-
Mahon, F.X.1
Rea, D.2
Guilhot, J.3
Guilhot, F.4
Huguet, F.5
Nicolini, F.6
-
46
-
-
84923081115
-
Long term follow-up after imatinib cessation for patients in deep molecular response: the update results of the STIM1 study
-
Mahon F.X., Rea D., Guilhot J., Guilhot F., Huguet F., Nicolini F.E., et al. Long term follow-up after imatinib cessation for patients in deep molecular response: the update results of the STIM1 study. Blood 2013, 122. (abstract 255).
-
(2013)
Blood
, pp. 122
-
-
Mahon, F.X.1
Rea, D.2
Guilhot, J.3
Guilhot, F.4
Huguet, F.5
Nicolini, F.E.6
-
47
-
-
84894050087
-
Preliminary report of the STIM2 study: a multicenter Stop Imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib
-
Mahon F.X., Nicolini F.E., Noël M., Escoffre M., Charbonnier A., Rea D., et al. Preliminary report of the STIM2 study: a multicenter Stop Imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood 2013, 122. (abstract 654).
-
(2013)
Blood
, pp. 122
-
-
Mahon, F.X.1
Nicolini, F.E.2
Noël, M.3
Escoffre, M.4
Charbonnier, A.5
Rea, D.6
-
48
-
-
84923116606
-
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath
-
Mahon F.X., Baccarani M., Mauro M.J., Hughes T.P., Saglio G., Savona M., et al. Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. J. Clin. Oncol. 2014, 32. (abstract TPS7124).
-
(2014)
J. Clin. Oncol.
, pp. 32
-
-
Mahon, F.X.1
Baccarani, M.2
Mauro, M.J.3
Hughes, T.P.4
Saglio, G.5
Savona, M.6
-
49
-
-
58149396984
-
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
-
Marin D., Milojkovic D., Olavarria E., Khorashad J.S., de Lavallade H., Reid A.G., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
-
(2008)
Blood
, vol.112
, pp. 4437-4444
-
-
Marin, D.1
Milojkovic, D.2
Olavarria, E.3
Khorashad, J.S.4
de Lavallade, H.5
Reid, A.G.6
-
50
-
-
77952467377
-
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
-
Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 2010, 28:2381-2388.
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2381-2388
-
-
Marin, D.1
Bazeos, A.2
Mahon, F.X.3
Eliasson, L.4
Milojkovic, D.5
Bua, M.6
-
51
-
-
84862907694
-
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
-
Marin D., Ibrahim A.R., Lucas C., Gerrard G., Wang L., Szydlo R.M., et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. 2012, 30:232-238.
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 232-238
-
-
Marin, D.1
Ibrahim, A.R.2
Lucas, C.3
Gerrard, G.4
Wang, L.5
Szydlo, R.M.6
-
52
-
-
84864041318
-
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib
-
Marin D., Hedgley C., Clark R.E., Apperley J., Foroni L., Milojkovic D., et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 2012, 120:291-294.
-
(2012)
Blood
, vol.120
, pp. 291-294
-
-
Marin, D.1
Hedgley, C.2
Clark, R.E.3
Apperley, J.4
Foroni, L.5
Milojkovic, D.6
-
54
-
-
84878263769
-
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
-
Neelakantan P., Gerrard G., Lucas C., Milojkovic D., May P., Wang L., et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013, 121:2739-2742.
-
(2013)
Blood
, vol.121
, pp. 2739-2742
-
-
Neelakantan, P.1
Gerrard, G.2
Lucas, C.3
Milojkovic, D.4
May, P.5
Wang, L.6
-
55
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003, 348:994-1004.
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
Gathmann, I.4
Baccarani, M.5
Cervantes, F.6
-
56
-
-
67650587143
-
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
-
Quintas-Cardama A., Kantarjian H., Jones D., Shan J., Borthakur G., Thomas D., et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009, 113:6315-6321.
-
(2009)
Blood
, vol.113
, pp. 6315-6321
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
Jones, D.3
Shan, J.4
Borthakur, G.5
Thomas, D.6
-
57
-
-
84974549180
-
ENESTpath: a phase III study to assess the effect of nilotinib treatment duration on treatment-free remission in chronic-phase chronic myeloid leukemia patients previously treated with imatinib: interim analysis from the first year of induction phase
-
Rea D., Gianantonio R., Cross N.C.P., Hellman A., Niederwiester D., Pungolino E., et al. ENESTpath: a phase III study to assess the effect of nilotinib treatment duration on treatment-free remission in chronic-phase chronic myeloid leukemia patients previously treated with imatinib: interim analysis from the first year of induction phase. Blood 2015, 126. (abstract 4040).
-
(2015)
Blood
, pp. 126
-
-
Rea, D.1
Gianantonio, R.2
Cross, N.C.P.3
Hellman, A.4
Niederwiester, D.5
Pungolino, E.6
-
58
-
-
84989311191
-
4.5 after switching from imatinib (IM) to nilotinib (NIL) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP): preliminary results from ENESTgoal
-
4.5 after switching from imatinib (IM) to nilotinib (NIL) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP): preliminary results from ENESTgoal. Blood 2015, 126. (abstract 4050).
-
(2015)
Blood
, pp. 126
-
-
Ritchie, E.K.1
Catchatourian, R.2
Klisovic, R.B.3
Deininger, M.W.4
Erba, H.P.5
Radich, J.P.6
-
59
-
-
84886917643
-
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
-
Ross D.M., Branford S., Seymour J.F., Schwarer A.P., Arthur C., Yeung D.T., et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013, 122:515-522.
-
(2013)
Blood
, vol.122
, pp. 515-522
-
-
Ross, D.M.1
Branford, S.2
Seymour, J.F.3
Schwarer, A.P.4
Arthur, C.5
Yeung, D.T.6
-
60
-
-
84923116605
-
First interim analysis of a pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial
-
Saussele S., Richter J., Guilhot J., Müller M.C., Dietz C., Porkka K., et al. First interim analysis of a pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial. Haematologica 2014, 99. (abstract LB2440).
-
(2014)
Haematologica
, pp. 99
-
-
Saussele, S.1
Richter, J.2
Guilhot, J.3
Müller, M.C.4
Dietz, C.5
Porkka, K.6
-
61
-
-
84867679530
-
Application of decision-analytic models in personalized medicine for CML treatment decisions made by payers, providers, and patients
-
Saverno K.R., Rochau U., Stenehjem D.D., Morley K., Siebert U., Brixner D.I. Application of decision-analytic models in personalized medicine for CML treatment decisions made by payers, providers, and patients. J. Manag. Care Pharm. 2012, 18:457-463.
-
(2012)
J. Manag. Care Pharm.
, vol.18
, pp. 457-463
-
-
Saverno, K.R.1
Rochau, U.2
Stenehjem, D.D.3
Morley, K.4
Siebert, U.5
Brixner, D.I.6
-
62
-
-
84899072118
-
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study
-
Shah N.P., Guilhot F., Cortes J.E., Schiffer C.A., le Coutre P., Brummendorf T.H., et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study. Blood 2014, 123:2317-2324.
-
(2014)
Blood
, vol.123
, pp. 2317-2324
-
-
Shah, N.P.1
Guilhot, F.2
Cortes, J.E.3
Schiffer, C.A.4
le Coutre, P.5
Brummendorf, T.H.6
-
63
-
-
80051573352
-
Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
-
Soverini S., Hochhaus A., Nicolini F.E., Gruber F., Lange T., Saglio G., et al. Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011, 118:1208-1215.
-
(2011)
Blood
, vol.118
, pp. 1208-1215
-
-
Soverini, S.1
Hochhaus, A.2
Nicolini, F.E.3
Gruber, F.4
Lange, T.5
Saglio, G.6
-
65
-
-
84989295223
-
Final results from SENSOR: switch to nilotinib after molecular suboptimal response (SoR) to frontline imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP)
-
Tanimoto M., Miyamura K., Miyamoto T., Yamamoto K., Taniwaki M., Kimura S., et al. Final results from SENSOR: switch to nilotinib after molecular suboptimal response (SoR) to frontline imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood 2014, 124. (abstract 1815).
-
(2014)
Blood
, pp. 124
-
-
Tanimoto, M.1
Miyamura, K.2
Miyamoto, T.3
Yamamoto, K.4
Taniwaki, M.5
Kimura, S.6
-
66
-
-
84966597257
-
-
Novartis Pharmaceuticals Corporation, East Hanover, NJ
-
Tasigna (nilotinib) [Package Insert] 2015, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
-
(2015)
Tasigna (nilotinib) [Package Insert]
-
-
-
67
-
-
77954936879
-
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib
-
White D.L., Dang P., Engler J., Frede A., Zrim S., Osborn M., et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J. Clin. Oncol. 2010, 28:2761-2767.
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2761-2767
-
-
White, D.L.1
Dang, P.2
Engler, J.3
Frede, A.4
Zrim, S.5
Osborn, M.6
-
68
-
-
43549100498
-
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
-
Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 2008, 111:3821-3829.
-
(2008)
Blood
, vol.111
, pp. 3821-3829
-
-
Wu, J.1
Meng, F.2
Lu, H.3
Kong, L.4
Bornmann, W.5
Peng, Z.6
-
69
-
-
84974610664
-
SENSOR interim data with mutation analysis: switching to nilotinib after molecular suboptimal response to imatinib in patients with chronic myeloid leukemia in chronic phase
-
Yamamoto K., Miyamura K., Miyamoto T., Tanimoto M., Taniwaki M., Kimura S., et al. SENSOR interim data with mutation analysis: switching to nilotinib after molecular suboptimal response to imatinib in patients with chronic myeloid leukemia in chronic phase. Haematologica 2014, 99. (abstract P882).
-
(2014)
Haematologica
, pp. 99
-
-
Yamamoto, K.1
Miyamura, K.2
Miyamoto, T.3
Tanimoto, M.4
Taniwaki, M.5
Kimura, S.6
-
70
-
-
84922365224
-
TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
-
Yeung D.T., Osborn M.P., White D.L., Branford S., Braley J., Herschtal A., et al. TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015, 125:915-923.
-
(2015)
Blood
, vol.125
, pp. 915-923
-
-
Yeung, D.T.1
Osborn, M.P.2
White, D.L.3
Branford, S.4
Braley, J.5
Herschtal, A.6
-
71
-
-
84974598204
-
Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib
-
(Epub ahead of print)
-
Yue Y., Gui X., He X., Chen Y., Pan J., Qiu H., et al. Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib. Hematology 2015, (Epub ahead of print).
-
(2015)
Hematology
-
-
Yue, Y.1
Gui, X.2
He, X.3
Chen, Y.4
Pan, J.5
Qiu, H.6
|